Vascular Endothelial Growth Factor (VEGF-a) in Fabry disease: Association with cutaneous and systemic manifestations with vascular involvement

Chiara Cadeddu, Anna Zampetti, Chiara De Waure, Claudio Feliciani, Walter Borsini, Maurizio Pieroni

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Fabry disease is an X-linked inherited metabolic disorder characterized by the deficiency of lysosomal α-galactosidase A enzyme. This leads to the accumulation, into lysosomes through the body, of glycosphingolipids, mainly Gb3. Skin involvement and progressive multi-organ failure are usually observed. Endothelium is the preferential target of the Gb3 storage that determines endothelial dysfunction and vasculopathy leading to the clinical manifestations of the disease. The serum levels of Vascular Endothelial Growth Factor-A (VEGF-A), a specific endothelial cell mitogen, were analyzed in Fabry patients to explore a possible association to the clinical manifestations with vascular involvement.
Original languageEnglish
Pages (from-to)933-939
Number of pages7
JournalCytokine
Volume61
DOIs
Publication statusPublished - 2013

Keywords

  • fabry
  • vegf

Fingerprint

Dive into the research topics of 'Vascular Endothelial Growth Factor (VEGF-a) in Fabry disease: Association with cutaneous and systemic manifestations with vascular involvement'. Together they form a unique fingerprint.

Cite this